ABVC vs ASTI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABVC Captures Institutional Edge (2โ2 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ABVC BioPharma, Inc. Common Stock (ABVC) driven by superior Growth & Margin, Momentum & Technical while ASTI counters with relative strength in Valuation, Options & Structure. Fundamentally, ABVC trades at N/M Forward P/E with 0.0% operating margin (+104.5% YoY revenue) versus ASTI at 14.4x Forward P/E and -2759.6% operating margin (+514.3% YoY). In options structure, ABVC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ASTI sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABVC | ASTI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $23.9M | $12.6M | Larger Scale | ABVC |
| Trailing P/E Ratio Valuation | N/M | 14.4x | Lower Multiple | ASTI |
| Forward P/E Ratio Valuation | N/M | 14.4x | Lower Multiple | ASTI |
| Revenue Growth (YoY) Growth | +104.5% | +514.3% | Higher Growth | ASTI |
| Operating Margin (TTM) Profitability | 0.0% | -2759.6% | Higher Margin | ABVC |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -52.7% | -111.3% | Higher ROE | ABVC |
| 52-Week Range Position Momentum | 7% ($1โ$3) | 0% ($1โ$10) | Stronger Trend | ABVC |
| Beta / 30D Volatility Risk Regime | 1.24ฮฒ ยท 44% Vol | 4.37ฮฒ ยท 123% Vol | Lower Realized Risk | ABVC |
| Unified Institutional Score Composite Signal | 47.4 / 100 (HOLD) | 44.5 / 100 (HOLD) | Higher Composite | ABVC |